Introducing a new section to Breast Cancer Research: Endocrinology and hormone therapy

被引：0
作者：
V Craig Jordan
Bruce AJ Ponder
机构：
[1] Lynn Sage Breast Cancer Research Program,Diana, Princess of Wales Professor of Cancer Research, Director
[2] Northwestern University Medical School,Head of CRC Department of Oncology
[3] Cambridge Institute for Medical Research,undefined
[4] Addenbrooke's Hospital,undefined
来源：
Breast Cancer Research | / 5卷
关键词：
antihormone; oestrogen receptor; selective oestrogen receptor modulation; tamoxifen;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Endocrine therapy is increasingly understood as the conceptual basis for the future treatment and prevention of breast cancer. Endocrine agents have considerably changed the approach to targeted treatment during the past two decades, and select endocrine agents have advanced the goal of preventing breast cancer. Progress has occurred because of a vigorous interaction between laboratory scientists and the clinical trials community. Breast Cancer Research is launching a new section on endocrinology and hormone therapy in order to invigorate this exchange and challenge our readers with novel concepts that might result in enhanced survival in breast cancer.
引用
收藏
相关论文
共 56 条
[1]  
Jensen EV(1998)Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1451-1467
[2]  
Jordan VC(2003)The estrogen receptor: a model for molecular medicine. The Dorothy P. Landon AACR Prize for Translational Research Clin Cancer Res 9 1980-1989
[3]  
Goss PE(2001)Aromatase inhibitors in the treatment and prevention of breast cancer J Clin Oncol 19 881-894
[4]  
Strasser K(2002)Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the women's health initiative randomized controlled trial JAMA 288 321-333
[5]  
Shumaker SA(2003)Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial JAMA 289 2651-2662
[6]  
Legault C(2002)Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 3396-3403
[7]  
Rapp SR(2002)Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 3386-3395
[8]  
Thal L(2001)High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy Breast Cancer Res Treat 67 111-116
[9]  
Wallace RB(2000)Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice Clin Cancer Res 6 2028-2036
[10]  
Ockene JK(undefined)undefined undefined undefined undefined-undefined
123456